LYRA THERAPEUTICS INC (LYRA)

US55234L1052 - Common Stock

4.72  -0.45 (-8.7%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
290K1.36M
368.97%		1.558M
14.56%		1.407M
-9.69%
EBITDA
YoY % growth
-42.62M
-92.76%		-53.92M
-26.51%		-65.25M
-21.01%		-60.7M
6.97%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-43.62M
-96.40%		-54.99M
-26.07%		-65.528M
-19.16%		-72.307M
-10.34%
Operating Margin
-15,041.38%-4,043.38%-4,205.91%-5,139.06%
EPS
YoY % growth
-3.35
83.42%		-1.75
47.76%		-1.25
28.57%		-1.03
17.58%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.27
39.26%
Revenue
Q2Q % growth		428.4K
4.49%
EBITDA
Q2Q % growth		-10.588MN/AN/AN/AN/A
EBIT
Q2Q % growth		-16.838M
2.73%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.22
42.11%		-0.320.1031.53%
Q3 2023
Q2Q % growth		 -0.27
32.50%		-0.320.0516.76%
Q2 2023
Q2Q % growth		 -0.32
25.58%		-0.430.1125.89%
Q1 2023
Q2Q % growth		 -0.44
18.52%		-0.37-0.07-18.18%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 146K
1,360.00%		396.576K-250.576K-63.18%
Q3 2023
Q2Q % growth		 540K
50.00%		379.032K160.968K42.47%
Q2 2023
Q2Q % growth		 460K
-13.21%		139.403K320.597K229.98%
Q1 2023
Q2Q % growth		 410K
-12.77%		162.69K247.31K152.01%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS5.59% 5.59% -5.03% 7.06%
Revenue40.47% 40.47% 17.74% 17.94%